Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Breast Neoplasms × nirogacestat × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 11 Desmoid Tumors 8 Neoplasms 3 Triple Negative Breast Neoplasms 1 Sarcoma, Kaposi 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms, Plasma Cell 1 Neoplasms by Histologic Type 1 Leukemia 1 Hematologic Diseases 1 HIV Infections 1 Granulosa cell tumor of the ovary 1 Corneal Diseases 1 Breast Neoplasms 1 Breast Cancer Metastatic 1 Blood Protein Disorders 1 Advanced Solid Tumors 1 AIDS-related Kaposi sarcoma 1

Interventions

Trastuzumab 556 Paclitaxel 513 Cyclophosphamide 491 Docetaxel 431 Capecitabine 372 Letrozole 336 Fulvestrant 292 Doxorubicin 262 Tamoxifen 245 Carboplatin 243 Anastrozole 211 Radiotherapy 201 exemestane 199 Epirubicin 180 Bevacizumab 178 palbociclib 170 Lapatinib 156 Vinorelbine 155 pertuzumab 152 Gemcitabine 151 pembrolizumab 146 Surveys and Questionnaires 124 Exercise 119 Magnetic Resonance Spectroscopy 117 eribulin 108 Albumin-Bound Paclitaxel 108 Fluorouracil 105 Blood Specimen Collection 103 130-nm albumin-bound paclitaxel 99 Everolimus 94

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02338531 2016-04-29

RHEA

Jules Bordet Institute

Phase 2 Withdrawn

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡